Cited by 157Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.

Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification

Open access

Ramjee, Vimal, Sperling, Laurence S., Jacobson, Terry A.·2011·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2011.05.009

Open this paper in CoChat — free account Open PDF

Abstract

With the emergence of new lipid risk markers and a growing cardiometabolic risk burden in the United States, there is a need to better integrate residual risk into cardiovascular disease (CVD) risk stratification. In anticipation of the Adult Treatment Panel IV (ATP IV) guidelines from the National Cholesterol Education Program (NCEP), there exists controversy regarding the comparative performance of the 2 foremost markers, apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (non-HDL-C), as they relate to the current standard of risk assessment and treatment: low-density lipoprotein cholesterol (LDL-C). Although some emerging markers may demonstrate better performance compared with LDL-C, certain fundamental characteristics intrinsic to a beneficial biomarker must be met prior to routine use. Collectively, studies have found that non-HDL-C and apoB perform better than LDL-C in CVD risk prediction, both on- and off-treatment, as well as in subclinical CVD risk prediction. The performance of non-HDL-C compared with apoB, however, has been a point of ongoing debate. Although both offer the practical benefits of accuracy independent of triglyceride level and prandial state, non-HDL-C proves to be the better marker of choice at this time, given established cutpoints with safe and achievable goals, no additional cost, and quick time to result with an easy mathematical calculation. The purpose of this review is to assess the performance of these parameters in this context and to discuss the considerations of implementation into clinical practice.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2011.05.009

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790

Flagged first, then by citations

Show all 57 references

2 of the 57 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–157 of 157

Prediction of future cardiovascular disease with an equation to estimate apolipoprotein B in patients with high cardiovascular risk: an analysis from the TNT and IDEAL study
Hwang, Y., Ahn, H. Y., Han, K. H., Park, H., & Park, C. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0549-8 · Cited by 6
Biochemistry laboratories should routinely report non-HDL-cholesterol
Preiss, D., & Neely, D. (2015) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563215594818 · Cited by 6
Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk
Björnson, E., Packard, C. J., & Borén, J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109010 · Cited by 6
Consensus statement on the management of dyslipidaemias in adults
Béliard, S., Bonnet, F., Bouhanick, B., Bruckert, É., Cariou, B., Charrière, S., Durlach, V., Moulin, P., Valéro, R., & Vergès, B. L. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.11.001 · Cited by 5
Lipid-modifying and antiatherosclerotic drugs
Gotto, A. M., & Opie, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00019-3 · Cited by 5
Association between the rs1805081 polymorphism of Niemann-Pick type C1 gene and cardiovascular disease in a sample of an Iranian population
Afzali, M., Hashemi, M. M., Tabatabaei, S. P., Tirgarfakheri, K., & Nakhaee, A. (2016) · Biomedical Reports · doi:10.3892/br.2016.802 · Cited by 6
The Good, the Bad, and the Atherogenic
Reiber, I., Mező, I., Márk, L., & Paragh, G. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.09.058 · Cited by 5
ApoB/LDL-C discordance as a predictor of atherosclerotic cardiovascular disease in genetically confirmed heterozygous familial hypercholesterolemia: A hypothesis-generating cohort study
Genedy, N., & Zouwail, S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.008 · Cited by 4
Tracking of apolipoprotein B levels measured in childhood and adolescence: systematic review and meta-analysis
Stanesby, O., Zhou, Z., Fonseca, R. C., Kidokoro, T., Otáhal, P., Fraser, B. J., Wu, F., Juonala, M., Viikari, J. S. A., Raitakari, O. T., et al. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-05350-0 · Cited by 4
Combined associations of cardiorespiratory fitness and grip strength with non-high-density lipoprotein cholesterol concentrations among Japanese children and adolescents
Kidokoro, T., & Miyashita, M. (2020) · The Journal of Physical Fitness and Sports Medicine · doi:10.7600/jpfsm.9.135 · Cited by 4
Associations of non-high-density lipoprotein cholesterol with metabolic syndrome and its components in Korean children and adolescents: the Korea National Health and Nutrition Examination Surveys 2008–2014
Kim, Y. M., Ys, K., & Shim, Y. S. (2018) · World Journal of Pediatrics · doi:10.1007/s12519-018-0160-8 · Cited by 4
The association of non-HDL-C, NHHR, RC, and RCII with coronary artery stenosis severity in patients with acute coronary syndrome combined with cardiometabolic multimorbidity
Zhang, P., Mo, D.-G., Dong, C., Zeng, W., Li, N., Wu, J., Wang, G., & Dai, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1701364 · Cited by 4
Cardiovascular Risk Assessment in Primary Prevention
Hussain, A., Rifai, M. A., Khalid, U., & Virani, S. S. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_1 · Cited by 3
Cholesterol
Pokharel, Y., Negi, S., & Virani, S. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00008-6 · Cited by 3
Optimal lipid targets for the new era of cardiovascular prevention
Ramjee, V., Eapen, D. J., & Sperling, L. S. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06478.x · Cited by 3
Self-citation
Differences in lipid parameters among statins treated patients with coronary arteriosclerosis – a pilot study
Burchardt, P., Żurawski, J., Kubacki, T., Żuchowski, B., & Wysocki, H. (2012) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201100260 · Cited by 2
Apolipoprotein B and Lipid Profile in Italian Children and Adolescents
Martino, F., Niglio, T., Martino, E., Paravati, V., SANCTIS, L. D., & Guardamagna, O. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11020044 · Cited by 2
Lipid-Lowering Drugs
Cook, G. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-39307-2.00024-2 · Cited by 2
The role of apoB measurement in Type 2 diabetic patients
Lee, B. K. H., Pratumvinit, B., & Thongtang, N. (2015) · Clinical Lipidology · doi:10.2217/clp.15.6 · Cited by 2
J-shaped association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and heart failure: a cross-sectional study
Lv, P., Zhao, C., & Shan, Y. (2026) · European journal of medical research · doi:10.1186/s40001-025-03825-4 · Cited by 1
Progress in risk assessment and management: Forecasting updates across international cholesterol guidelines
Razavi, A. C., Sokolsky, M., Belanger, M., Blazoski, C. M., Spitz, J. A., Sperling, L. S., Blumenthal, R. S., & Whelton, S. P. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101417 · Cited by 1
Self-citation
Association between non-HDL-cholesterol to HDL-cholesterol ratio (NHHR) and COPD: a cross-sectional study of 11,082 Chinese adults with predictive nomogram development
Li, X., Wang, Y., & Zhao, X. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04132-2 · Cited by 1
Efecto de la dieta nórdica en el control de los factores de riesgo de enfermedad cardiovascular: Revisión sistemática
de Nobrega, S. C., Cornejo, V., Leal-Witt, M. J., & Durán‐Agüero, S. (2021) · Revista chilena de nutrición · doi:10.4067/s0717-75182021000400640 · Cited by 1
Association between the variability of non-high-density lipoprotein cholesterol and the neutrophil-to-lymphocyte ratio in patients with coronary heart disease
Chen, Y., Zhang, S., Tao, Y., Hu, W., Li, D., Shen, X., Li, Y., Lin, M., Zhang, W., Liu, X., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1254125 · Cited by 1
Portuguese Lipid Study (e_LIPID)
Chora, J. R., Alves, A. C., Mariano, C., Rato, Q., Antunes, M. C. D. S., & Bourbon, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226965 · Cited by 1
Dyslipidémie
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.015 · Cited by 1
Lipids, Atherogenic Dyslipidemia, and Therapy
Levine, T. B., & Levine, A. B. (2012) · Wiley eBooks · doi:10.1002/9781118480045.ch13 · Cited by 1
PONTIFÍCIA UNIVERSIDADE CATÓLICA DO RIO GRANDE DO SUL PROGRAMA DE PÓS-GRADUAÇÃO EM MEDICINA E CIÊNCIAS DA SAÚDE ÁREA DE CONCENTRAÇÃO: CLÍNICA MÉDICA DISSERTAÇÃO DE MESTRADO
Radaelli, G., & Alegre, P. (2011) · Cited by 1
KLINISCHE CHEMIE UND LABORATORIUMSMEDIZIN
Schmitz, G., & Medizin, F. F. (2014) · Cited by 1
Commentary on High-density Lipoprotein Versus Low-density Lipoprotein Therapy and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes by Nikolaos Papageorgiou et al.
Owens, D. A., & Tomkin, G. H. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x1404181008143841 · Cited by 1
Klinische Befunde und rationelle Differenzialdiagnostik der diabetischen Dyslipidämie
von Eckardstein, A. (2012) · Der Diabetologe · doi:10.1007/s11428-012-0890-5
Risk Factors and Prevention, Including Hyperlipidemia
Gotto, A. M., & Farmer, J. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6705-2_23
Hypertriglyceridemic-Waist Phenotype is a Useful Global Assessment Tool for Predicting Acute Myocardial Infarction
Egeland, G. M. (2015) · Journal of Cardiovascular Diseases & Diagnosis · doi:10.4172/2329-9517.1000207
The Effects of Oats and Oat‐β‐Glucan on Blood Lipoproteins and Risk for Cardiovascular Disease
Rains, T. M., & Maki, K. C. (2013) · doi:10.1002/9781118354100.ch9
Risk Stratification in Clinical Practice
Mendys, P., Joodi, G., & Simpson, R. J. (2015) · Atherosclerosis · doi:10.1002/9781118828533.ch38
Az egészséges táplálkozás és a fizikai aktivitás hatása a non-HDL-koleszterin-szintre cardiovascularis betegségtől mentes, nem diabeteses elhízott személyekben
Móczár, C. (2015) · Orvosi Hetilap · doi:10.1556/650.2015.30269
Stężenie cholesterolu nie-HDL u nastolatków obciążonych klinicznymi czynnikami ryzyka miażdżycy
Obuchowicz, A. K., Kniażewska, M., Żmudzińska-Kitczak, J., & Jarecka, B. (2014) · Pediatria Polska · doi:10.1016/j.pepo.2014.07.005
Comparable Incremental Value of Standard and Nonstandard Lipids for Coronary Heart Disease Risk Assessment in Elderly Adults: The Three City Study
Straczek, C., Martí-Soler, H., Tafflet, M., Perier, M., Dupuy, A., Tzourio, C., Barberger‐Gateau, P., & Empana, J. P. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12347
Façons d’identifier et de prendre en charge la dyslipidémie athérogène
Bosomworth, N. J. (2013) · Europe PMC (PubMed Central)
NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL VERSUS APOLIPOPROTEIN B AS PREDICTORS FOR CORONARY HEART DISEASE
Aggarwal, J., Reddy, S., & Nagtilak, S. (2014) · International Journal of Pharma and Bio Sciences
Biomarker des Lipoproteinstoffwechsels
von Eckardstein, A. (2015) · Cardiovascular Medicine · doi:10.4414/cvm.2015.00297
Comparative impact of implementing the 2013 or 2014 cholesterol guideline on vascular events in a quality improvement network
Egan, B. M., Sutherland, S. E., Childers, W. F., Dahlheimer, R. M., Helmrich, G. A., Lapeyrolerie, D. A., Markle, N., Murphy, D. W., Simmons, L., Davis, R. A., et al. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944715624854
[Hereditary angioedema in organs of the head and neck as an indication for emergency tracheotomy].
Mitrović, S., Jovićević, J., Jović, R. M., & Mitić, I. (2001) · PubMed
Façons d’identifier et de prendre en charge la dyslipidémie athérogène
Bosomworth, N. J. (2013) · Canadian Family Physician
Newer Lipid Markers: Apolipoprotein B, LDL Particle Concentration, and Triglyceride-Rich Lipoproteins – When Are They Needed?
Quispe, R., Martin, S. S., & Jones, S. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-42982-3_12
Nutritional Factors Impacting Intestinal Lipid Metabolism Using a Model of Low Birth Weight Swine
Fontaine, M. A. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3dr2pq51
Apolipoproten B, LDL Cholesterol and apoB/apoA-I Ratio in Patients With Stable Angina
Handayani, O., & Sargowo, D. (2017) · Indonesian Journal of Cardiology · doi:10.30701/ijc.v37i1.550
Reply
Ramjee, V., Sperling, L. S., & Jacobson, T. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.10.866
Self-citation
Additional file 1 of Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles
Xue, Y., Shen, J., Hong, W., Zhou, W., Xiang, Z., Zhu, Y., Huang, C., & Luo, S. (2021) · Figshare · doi:10.6084/m9.figshare.14551908
Additional file 4 of Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles
Xue, Y., Shen, J., Hong, W., Zhou, W., Xiang, Z., Zhu, Y., Huang, C., & Luo, S. (2021) · Figshare · doi:10.6084/m9.figshare.14551917
Additional file 5 of Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles
Xue, Y., Shen, J., Hong, W., Zhou, W., Xiang, Z., Zhu, Y., Huang, C., & Luo, S. (2021) · Figshare · doi:10.6084/m9.figshare.14551920
Additional file 3 of Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles
Xue, Y., Shen, J., Hong, W., Zhou, W., Xiang, Z., Zhu, Y., Huang, C., & Luo, S. (2021) · Figshare · doi:10.6084/m9.figshare.14551914
Additional file 2 of Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles
Xue, Y., Shen, J., Hong, W., Zhou, W., Xiang, Z., Zhu, Y., Huang, C., & Luo, S. (2021) · Figshare · doi:10.6084/m9.figshare.14551911
Therapeutic approaches to dyslipidaemia in Unani medicine: a narrative review
Rouf, T., & Ahmed, I. (2026) · Journal of Holistic Integrative Pharmacy · doi:10.1016/j.jhip.2026.01.002
Le petit déjeuner standardisé. Un outil diagnostique du statut glycémique et des modifications cardiovasculaires postprandiales ? : Comparaison vs la charge en glucose ; et explorations cardiovasculaires sous saxagliptine vs placebo chez des patients intolérants au glucose
Rezki, A. (2019) · theses.fr (ABES) · doi:10.70675/392902d9z7810z4025zb9afz3081c32bac5d
Integrating measures of remnant cholesterol and inflammation: risky business?
Bennett, J., Medina‐Inojosa, J. R., & Sperling, L. S. (2026) · Archives of Medical Science · doi:10.5114/aoms/221520
Self-citation
Combination pitavastatin–ezetimibe therapy for hypercholesterolemia and mixed dyslipidemia: a systematic review and meta-analysis
Abbas, M. S., Batool, A., Hussain, M., Hassan, M., Sohaib, A., Ahmed, T., Athar, M., Khan, S., Kanwal, W., Akbar, M. A., et al. (2026) · Future Cardiology · doi:10.1080/14796678.2026.2676249

Authors: Ramjee, V., Sperling, L. S., & Jacobson, T. A.
Affiliations: Emory University (US)
Corresponding author: Jacobson, Terry A.
ORCID: Ramjee, Vimal
Sperling, Laurence S.
Jacobson, Terry A.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2011-07
Volume: 58
Issue: 5
Pages: 457-463
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2011.05.009
OpenAlex: W1571892311
Cited by: 157
References: 57
Citations by year: 2026: 7 · 2025: 4 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 9 · 2020: 8 · 2019: 10 · 2018: 7 · 2017: 8 · 2016: 11 · 2015: 19 · 2014: 15 · 2013: 28 · 2012: 15
FWCI: 3.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 746 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: non-HDL cholesterol, apolipoprotein B, cardiovascular risk stratification, residual cardiovascular risk, LDL cholesterol
MeSH terms: Apolipoproteins B, Cardiovascular Diseases, Coronary Artery Disease, Humans, Lipoproteins, Biomarkers, Practice Guidelines as Topic, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks